PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33954816-0 2022 Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. Decitabine 15-25 tumor protein p53 Homo sapiens 40-44 32030889-9 2020 In 34 patients who received treatment with decitabine, 25 with TP53 mutations had higher overall response rate than those with wild-type TP53 (60% vs 22.2%, P = .03). Decitabine 43-53 tumor protein p53 Homo sapiens 63-67 33627797-0 2021 Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations. Decitabine 0-10 tumor protein p53 Homo sapiens 94-98 33932107-4 2021 Prophylactic use of decitabine followed by DLI was planned in patients with TP53 or epigenetic modifier gene mutations. Decitabine 20-30 tumor protein p53 Homo sapiens 76-80 33321328-6 2021 E7 expression was restored by 5-Aza-2 deoxycytidine in p53 KO lines, suggesting a role of DNA methylation in this process. Decitabine 30-51 tumor protein p53 Homo sapiens 55-58 33399480-0 2021 Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Decitabine 0-10 tumor protein p53 Homo sapiens 88-92 33323826-0 2020 Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation: a single-center analysis. Decitabine 23-33 tumor protein p53 Homo sapiens 195-199 33001991-2 2020 Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional characteristics of TP53 mutant are heterogeneous, as reflected in multiple functional TP53 classifications and their impact in patients treated with azacitidine is less clear. Decitabine 139-149 tumor protein p53 Homo sapiens 10-14 33001991-2 2020 Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional characteristics of TP53 mutant are heterogeneous, as reflected in multiple functional TP53 classifications and their impact in patients treated with azacitidine is less clear. Decitabine 139-149 tumor protein p53 Homo sapiens 199-203 33001991-2 2020 Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional characteristics of TP53 mutant are heterogeneous, as reflected in multiple functional TP53 classifications and their impact in patients treated with azacitidine is less clear. Decitabine 139-149 tumor protein p53 Homo sapiens 199-203 32504186-0 2020 Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. Decitabine 65-75 tumor protein p53 Homo sapiens 47-51 32504186-1 2020 TP53 aberrations reportedly predict favorable responses to decitabine (DAC) in acute myeloid leukemia (AML). Decitabine 59-69 tumor protein p53 Homo sapiens 0-4 32504186-1 2020 TP53 aberrations reportedly predict favorable responses to decitabine (DAC) in acute myeloid leukemia (AML). Decitabine 71-74 tumor protein p53 Homo sapiens 0-4 32030889-9 2020 In 34 patients who received treatment with decitabine, 25 with TP53 mutations had higher overall response rate than those with wild-type TP53 (60% vs 22.2%, P = .03). Decitabine 43-53 tumor protein p53 Homo sapiens 137-141 29143344-4 2017 5-Aza-dC inhibited E6 and E7 expression and up-regulated p53, p21, and Rb expression. Decitabine 0-8 tumor protein p53 Homo sapiens 57-60 30792212-0 2019 TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies. Decitabine 80-90 tumor protein p53 Homo sapiens 0-4 30792212-0 2019 TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies. Decitabine 80-90 tumor protein p53 Homo sapiens 42-46 31418371-4 2019 The expression of P53 mRNA increased in KMS-18 cells after treatment of decitabine (P<0.05). Decitabine 72-82 tumor protein p53 Homo sapiens 18-21 31418371-5 2019 The methylation status of the P53 gene promoter in KMS-18 cells could be partially reversed by decitabine. Decitabine 95-105 tumor protein p53 Homo sapiens 30-33 31418371-6 2019 CONCLUSION: Decitabine can inhibit the proliferation of KMS-18 cells and induce their apoptosis, its mechanism ralates with partially reversing the methylation of P53 gene promoter in KMS-18 cells. Decitabine 12-22 tumor protein p53 Homo sapiens 163-166 30466751-3 2018 Decitabine is emerging as an alternative treatment option for patients with TP53 mutated AML, although the agent has not been associated with deep molecular remissions and requires additional consolidation. Decitabine 0-10 tumor protein p53 Homo sapiens 76-80 29735783-8 2018 CONCLUSION: We were able to demonstrate Wnt/ beta-catenin pathway modulation through E-cadherin up-regulation induced by 5aza-dC and TSA treatments, under an activation-pathway background, like CTNNB1 and TP53 mutations. Decitabine 121-128 tumor protein p53 Homo sapiens 205-209 30501707-10 2018 Among 87 patients received decitabine treatment, the TP53 gene mutation occured in 11 (12.6%) patients. Decitabine 27-37 tumor protein p53 Homo sapiens 53-57 30501707-12 2018 Multivariate logistic regression model showed that the complex karyotype, Plt count doubling after 1 course treatment, TP53 mulation and high expression of hENT1 mRNA were the independent prognostic factors for predicting the CR after decitabine treatment. Decitabine 235-245 tumor protein p53 Homo sapiens 119-123 29877251-9 2018 Recently, increasing attention has been paid to a report, according to which, majority of the patients with TP53 mutations showed good response to a higher dose of decitabine. Decitabine 164-174 tumor protein p53 Homo sapiens 108-112 28802167-11 2017 Bioinformatics analyses predicted that 5-Aza-dC functions as a p53 inducer, radiosensitizer, and inhibitor of some enzymes. Decitabine 39-47 tumor protein p53 Homo sapiens 63-66 28802167-13 2017 In this study, we provide experimental evidence showing HDM2 is one of the targets of 5-AZA-dC leading to activation of p53 pathway and growth arrest of cells. Decitabine 86-94 tumor protein p53 Homo sapiens 120-123 28225682-0 2017 Decitabine in TP53-Mutated AML. Decitabine 0-10 tumor protein p53 Homo sapiens 14-18 28453190-8 2017 The increased expression of genes involved in the NGFR-MAPK10-TP53-Bax/Bcl2 pathway during incubation with AZA plus everolimus was validated by western blotting in MZ-CRC-1 cells. Decitabine 107-110 tumor protein p53 Homo sapiens 62-66 27984642-0 2017 TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Decitabine 23-33 tumor protein p53 Homo sapiens 0-4 28229579-0 2017 Decitabine in TP53-Mutated AML. Decitabine 0-10 tumor protein p53 Homo sapiens 14-18 27984642-9 2017 In summary, TP53 mutations might predict decitabine-induced complete responses in patients with MDS. Decitabine 41-51 tumor protein p53 Homo sapiens 12-16 27995947-0 2017 Haematological cancer: TP53 mutations sensitize to decitabine. Decitabine 51-61 tumor protein p53 Homo sapiens 23-27 28129641-4 2017 AML cells with p53 mutations in humans treated with decitabine are killed by differentiation or senescense, but then relapse at a high rate becoming drug resistant. Decitabine 52-62 tumor protein p53 Homo sapiens 15-18 25409339-4 2016 Simultaneous treatment of donor cells with TSA (50nM) and 5azadC (7.5nM) resulted in higher in vitro development to the blastocyst stage, reduction of the apoptotic index and the global level of H3K27 me3 and altered expression levels of HDAC1, P53, CASPASE3, CASPASE9 and DNMT3a in cloned blastocysts. Decitabine 58-64 tumor protein p53 Homo sapiens 245-248 28484169-8 2017 In the case of TP53 mutations, prognosis is poor for both hematopoietic stem cell transplantation and AZA treatment, although, patients with TP53 mutations have been shown to respond favorably to decitabine administration for 10 days. Decitabine 196-206 tumor protein p53 Homo sapiens 15-19 28484169-8 2017 In the case of TP53 mutations, prognosis is poor for both hematopoietic stem cell transplantation and AZA treatment, although, patients with TP53 mutations have been shown to respond favorably to decitabine administration for 10 days. Decitabine 196-206 tumor protein p53 Homo sapiens 141-145 27959731-10 2016 CONCLUSIONS: Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable risk, TP53 mutations, or both had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine. Decitabine 252-262 tumor protein p53 Homo sapiens 107-111 26258493-5 2016 DNA demethylation with 5-aza-2"-deoxycytidine restored GLS2 mRNA and protein content in human GB cell lines with both mutated (T98G) and wild-type (U87MG) p53 and reduced the methylation of CpG1 (promoter region island), and CpG2 (first intron island) in both cell lines. Decitabine 23-45 tumor protein p53 Homo sapiens 155-158 23582784-0 2013 Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Decitabine 0-10 tumor protein p53 Homo sapiens 96-99 26384351-2 2015 Cytotoxic effect was increased by decitabine through activation of p53 and inhibition of c-Myc, Survivin and Bcl-2. Decitabine 34-44 tumor protein p53 Homo sapiens 67-70 23810988-6 2013 With ER-alpha positive cells AZA increased the abundance of the tumour suppressor gene, p53 and induced demethylation of the IGFBP-3 promoter, whereas with ER negative cells, AZA epigenetically increased the transcription factor AP2-alpha, which when silenced prevented the increase in IGFBP-3. Decitabine 29-32 tumor protein p53 Homo sapiens 88-91 25751281-5 2015 In temozolomide-resistant GBM cells, decitabine can potentiate the cytotoxic DNA alkylation by counteracting cytosine methylation and reactivating tumor suppressor genes, such as p53 and p21. Decitabine 37-47 tumor protein p53 Homo sapiens 179-182 25621498-4 2015 Preclinical studies suggest that noncytotoxic concentrations of the DNA methyltransferase 1 (DNMT1) inhibitor decitabine produce p53-independent cell-cycle exits by reversing aberrant epigenetic repression of proliferation-terminating (MYC-antagonizing) differentiation genes in cancer cells. Decitabine 110-120 tumor protein p53 Homo sapiens 129-132 24676336-12 2014 For the TSA+DAC group, higher levels of p53, p21, cyclin B1 and Chk1 were detected, concomitant with lower levels of CDK1, when compared to the control group. Decitabine 12-15 tumor protein p53 Homo sapiens 40-43 25140197-0 2014 Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells. Decitabine 0-10 tumor protein p53 Homo sapiens 107-110 24163369-11 2013 These results identify NEK2 as a novel p53-repressed gene, illustrate that its repression by 5aza-dC is specific and associated with nucleosome reorganization, and provide evidence that identification of partially methylated regions can reveal novel p53 target genes. Decitabine 93-100 tumor protein p53 Homo sapiens 39-42 24163369-11 2013 These results identify NEK2 as a novel p53-repressed gene, illustrate that its repression by 5aza-dC is specific and associated with nucleosome reorganization, and provide evidence that identification of partially methylated regions can reveal novel p53 target genes. Decitabine 93-100 tumor protein p53 Homo sapiens 250-253 23582784-5 2013 DNA flow cytometric analyses indicated that decitabine induced a G2/M arrest in AGS gastric and A549 lung carcinoma cell lines, which have wild type p53. Decitabine 44-54 tumor protein p53 Homo sapiens 149-152 23582784-7 2013 However, similar results were found using the A549 cell line, where decitabine induced a dramatic up-regulation of both p53 and p21 expression, and the increased levels of p21 were associated with increased binding of p21 with Cdks, cyclin A, and cyclin B1. Decitabine 68-78 tumor protein p53 Homo sapiens 120-123 23582784-8 2013 Knockdown of p53 by small interfering RNA (siRNA) markedly abolished p53 induction by decitabine in AGS cells, yet p53 siRNA had no attenuating effect on p21 induction. Decitabine 86-96 tumor protein p53 Homo sapiens 13-16 23582784-8 2013 Knockdown of p53 by small interfering RNA (siRNA) markedly abolished p53 induction by decitabine in AGS cells, yet p53 siRNA had no attenuating effect on p21 induction. Decitabine 86-96 tumor protein p53 Homo sapiens 69-72 23582784-8 2013 Knockdown of p53 by small interfering RNA (siRNA) markedly abolished p53 induction by decitabine in AGS cells, yet p53 siRNA had no attenuating effect on p21 induction. Decitabine 86-96 tumor protein p53 Homo sapiens 69-72 23582784-10 2013 We also observed that decitabine strongly induced G2/M arrest associated with p21 induction in both p53 allele-null (-/-) HCT116 and wild type p53 (+/+) HCT116 cell lines. Decitabine 22-32 tumor protein p53 Homo sapiens 100-103 23582784-10 2013 We also observed that decitabine strongly induced G2/M arrest associated with p21 induction in both p53 allele-null (-/-) HCT116 and wild type p53 (+/+) HCT116 cell lines. Decitabine 22-32 tumor protein p53 Homo sapiens 143-146 23079745-10 2013 Furthermore, treatment of HCC cells with 5-aza-2"-deoxycytidine or ectopic expression of wildtype but not mutated p53 restored miR-125a-5p and miR-125b expression and inhibited tumor cell growth, suggesting their regulation by promoter methylation and p53 activity. Decitabine 41-63 tumor protein p53 Homo sapiens 252-255 23201008-0 2013 Cytotoxicity of 5-Aza-2"-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A). Decitabine 16-38 tumor protein p53 Homo sapiens 92-95 23141446-14 2012 There might be antagonistic effect between p53 and 5-aza-dC. Decitabine 51-59 tumor protein p53 Homo sapiens 43-46 24319226-2 2013 For example, 5-azacytidine and decitabine produce remissions and better overall survival in MDS with high-risk chromosome abnormalities at a surprisingly high rate, consistent with experimental observations that noncytotoxic DNA methyltransferase depletion by 5-azacytidine/decitabine can trigger cell cycle exit independently of p53, thus circumventing a basis for resistance to apoptosis-based DNA-damaging therapy. Decitabine 31-41 tumor protein p53 Homo sapiens 330-333 22429346-4 2012 Hypermethylation of the promoters of the p53-BAX mitochondrial apoptosis genes cyclin-dependent kinase inhibitor 2A (CDKN2A), death-associated protein kinase 1 (DAPK1) and PYD and CARD domain containing (PYCARD) was detected by methylation-specific polymerase chain reaction, with and without DAC treatment. Decitabine 293-296 tumor protein p53 Homo sapiens 41-44 21455989-0 2012 The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. Decitabine 52-62 tumor protein p53 Homo sapiens 120-123 21455989-11 2012 Our results suggest that the mitochondrial apoptotic pathway activated by decitabine and zebularine in p53 mutant leukemic T cells depends mainly on the induction of DNA damage. Decitabine 74-84 tumor protein p53 Homo sapiens 103-106 22429346-8 2012 CONCLUSIONS: DAC induces apoptosis of QBC939 cells by reactivation of hypermethylated p53-BAX mitchondrial apoptosis genes in cholangiocarcinoma cells. Decitabine 13-16 tumor protein p53 Homo sapiens 86-89 23300844-0 2012 Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. Decitabine 96-115 tumor protein p53 Homo sapiens 164-167 21550660-4 2011 Notably, when 5-AzadC was combined with HDACI MS-275, apoptosis in MV4-11 TP53 R248W cells was significantly enhanced in parallel with activation of the caspase cascade, up-regulation of p21waf1 and gamma-H2AX, and down-regulation of Mcl-1. Decitabine 14-21 tumor protein p53 Homo sapiens 74-78 21701495-3 2011 In vitro and in vivo regimens of the deoxycytidine analogue decitabine that deplete the chromatin-modifying enzyme DNA methyl-transferase 1 without phosphorylating p53 or inducing early apoptosis were determined. Decitabine 60-70 tumor protein p53 Homo sapiens 164-167 21701495-4 2011 These decitabine regimens but not equimolar DNA-damaging cytarabine upregulated the key late differentiation factors CCAAT enhancer-binding protein e and p27/cyclin dependent kinase inhibitor 1B (CDKN1B), induced cellular differentiation and terminated AML cell cycle, even in cytarabine-resistant p53- and p16/CDKN2A-null AML cells. Decitabine 6-16 tumor protein p53 Homo sapiens 298-301 21725200-3 2011 We report that the primary molecular mechanism of decitabine-depletion of DNA methyltransferase-1 following its "suicide" inactivation-is not absolutely associated with cell cycle progression in HCT 116 colon cancer cells, but is associated with their p53 genotype. Decitabine 50-60 tumor protein p53 Homo sapiens 252-255 21725200-5 2011 Secondary changes in CpG methylation occurred only in growing cells ~24-48 h after decitabine treatment; these epigenetic changes coincided with p53 accumulation, an index of DNA damage. Decitabine 83-93 tumor protein p53 Homo sapiens 145-148 21550660-5 2011 Interestingly, inhibition of caspase 3 by the pan-caspase inhibitor attenuated the combination of 5-AzadC and MS-275-mediated apoptosis and down-regulation of Mcl-1 in MV4-11 TP53 R248W cells. Decitabine 98-105 tumor protein p53 Homo sapiens 175-179 21550660-8 2011 Combination of 5-AzadC and MS-275 may be a promising treatment strategy for individuals with leukemia in which TP53 is inactivated. Decitabine 15-22 tumor protein p53 Homo sapiens 111-115 19179467-0 2009 Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Decitabine 109-119 tumor protein p53 Homo sapiens 15-18 19638426-7 2010 Treating methylated CRC cell lines with 5-aza-2"-deoxycytidine restored p53-induced IGFBP7 expression. Decitabine 40-62 tumor protein p53 Homo sapiens 72-75 19233506-7 2009 Interestingly, both strategies substantially decrease cell survival of MPM cells but the antitumor activity of Decitabine, differently from DNMT1 silencing, is mediated, at least in part, by a p53-independent p21 upregulation, and is characterized by the arrest of MPM cells at the G2/M phase of the cell cycle. Decitabine 111-121 tumor protein p53 Homo sapiens 193-196 19363521-6 2009 Our data indicates that demethylation of the survivin promoter by decitabine results in p53-dependent survivin repression and that p53 binding can be inhibited by DNA methylation. Decitabine 66-76 tumor protein p53 Homo sapiens 88-91 19859801-5 2010 We also found that treating MCF7 cells with DAC restored induction of DFNA5 by p53, as well as by two other p53 family genes, p63gamma and p73beta. Decitabine 44-47 tumor protein p53 Homo sapiens 79-82 19859801-5 2010 We also found that treating MCF7 cells with DAC restored induction of DFNA5 by p53, as well as by two other p53 family genes, p63gamma and p73beta. Decitabine 44-47 tumor protein p53 Homo sapiens 108-111 19010910-1 2008 While the therapeutic activity of the deoxycytidine analogue decitabine is thought to reflect its ability to reactivate methylation-silenced genes, this agent is also known to trigger p53-dependent DNA damage responses. Decitabine 61-71 tumor protein p53 Homo sapiens 184-187 19159630-0 2009 Possible involvement of activation of P53/P21 and demethylation of RUNX 3 in the cytotoxicity against Lovo cells induced by 5-Aza-2"-deoxycytidine. Decitabine 124-146 tumor protein p53 Homo sapiens 38-45 19010910-2 2008 Here, we report that p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a robust transcriptional target of decitabine. Decitabine 112-122 tumor protein p53 Homo sapiens 21-24 19010910-3 2008 In cancer cells, decitabine treatment induces p53R2 mRNA expression, protein expression, and promoter activity in a p53-dependent manner. Decitabine 17-27 tumor protein p53 Homo sapiens 46-49 16025287-5 2005 Treatment with 5-aza-2"-deoxycytidine (5-aza-dC) led to up-regulated expression of TP53 mRNA and protein in U87MG and T98G cells, suggesting that promoter methylation is associated with reduced expression in some malignant glioma cells. Decitabine 15-37 tumor protein p53 Homo sapiens 83-87 18608210-0 2008 5-Aza-2"-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis. Decitabine 0-22 tumor protein p53 Homo sapiens 57-60 18608210-0 2008 5-Aza-2"-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis. Decitabine 0-22 tumor protein p53 Homo sapiens 90-93 18608210-2 2008 The lack of p53 inducibility of Noxa was restored by treatment with the DNA methyltransferase inhibitor 5-Aza-2"-deoxycytidine (5-aza-CdR). Decitabine 104-126 tumor protein p53 Homo sapiens 12-15 16131836-5 2005 Global genomic DNA demethylation induced by 5-Aza-deoxycytidine activates the p53 signaling pathway and induces apoptosis, suggesting that DNA methylation mediated by Dnmts is associated with p53 signaling in maintaining genome stability. Decitabine 44-63 tumor protein p53 Homo sapiens 78-81 16131836-5 2005 Global genomic DNA demethylation induced by 5-Aza-deoxycytidine activates the p53 signaling pathway and induces apoptosis, suggesting that DNA methylation mediated by Dnmts is associated with p53 signaling in maintaining genome stability. Decitabine 44-63 tumor protein p53 Homo sapiens 192-195 17977830-0 2008 An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2"-deoxycytidine treatment. Decitabine 153-175 tumor protein p53 Homo sapiens 121-124 17977830-3 2008 In this study, the relationship between p53 activation and its posttranslational modifications was investigated in the human cancer cell lines A549 and HCT116 in response to 5-aza-2"-deoxycytidine (5-aza-CdR) or cytarabine treatment. Decitabine 174-196 tumor protein p53 Homo sapiens 40-43 16025287-5 2005 Treatment with 5-aza-2"-deoxycytidine (5-aza-dC) led to up-regulated expression of TP53 mRNA and protein in U87MG and T98G cells, suggesting that promoter methylation is associated with reduced expression in some malignant glioma cells. Decitabine 39-47 tumor protein p53 Homo sapiens 83-87 15609309-0 2005 5-Aza-2"-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Decitabine 0-22 tumor protein p53 Homo sapiens 84-87 11259619-0 2001 Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2"-deoxycytidine. Decitabine 95-117 tumor protein p53 Homo sapiens 18-21 15273730-0 2004 5-aza-2"-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Decitabine 0-22 tumor protein p53 Homo sapiens 73-76 15273730-2 2004 However, when cells were treated with DAC and infected with a low dose of a recombinant wild-type p53 adenovirus vector (Ad-p53), a synergistic growth inhibitory effect was observed. Decitabine 38-41 tumor protein p53 Homo sapiens 98-101 15273730-2 2004 However, when cells were treated with DAC and infected with a low dose of a recombinant wild-type p53 adenovirus vector (Ad-p53), a synergistic growth inhibitory effect was observed. Decitabine 38-41 tumor protein p53 Homo sapiens 124-127 15273730-4 2004 Selective blockage of caspase-9 activities by Z-LEHD-FMK completely attenuated DAC-induced enhancement of apoptosis mediated by Ad-p53 infection, and ectopic overexpression of procaspase-9 sensitized cells to Ad-p53-induced apoptosis in p53-null cells. Decitabine 79-82 tumor protein p53 Homo sapiens 131-134 15273730-4 2004 Selective blockage of caspase-9 activities by Z-LEHD-FMK completely attenuated DAC-induced enhancement of apoptosis mediated by Ad-p53 infection, and ectopic overexpression of procaspase-9 sensitized cells to Ad-p53-induced apoptosis in p53-null cells. Decitabine 79-82 tumor protein p53 Homo sapiens 212-215 15273730-4 2004 Selective blockage of caspase-9 activities by Z-LEHD-FMK completely attenuated DAC-induced enhancement of apoptosis mediated by Ad-p53 infection, and ectopic overexpression of procaspase-9 sensitized cells to Ad-p53-induced apoptosis in p53-null cells. Decitabine 79-82 tumor protein p53 Homo sapiens 212-215 14722112-0 2004 5-aza-2"-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. Decitabine 0-22 tumor protein p53 Homo sapiens 37-40 12700649-6 2003 The p53-binding region in the first intron of the Fas gene was partially methylated in Caco(2), and 5-azadC potentiated Ad-wtp53-induced upregulation of Fas expression. Decitabine 100-107 tumor protein p53 Homo sapiens 4-7 11306450-6 2001 Treatment with the demethylating agent 5-aza-2"-deoxycytidine was able to reinternalize MDM2 to the nucleus, and p53 expression was restored. Decitabine 39-61 tumor protein p53 Homo sapiens 113-116 11092975-6 2000 The silent TP53 could be reactivated by treatment with the demethylating agent 5-azadeoxycytidine. Decitabine 79-97 tumor protein p53 Homo sapiens 11-15 34534222-6 2021 The aim of the present study is to test the effect of 5-AzaD on growth of human squamous cell carcinoma (FaDu), a HPV(-) and p53 mutated cells, in vitro and in vivo. Decitabine 54-60 tumor protein p53 Homo sapiens 125-128 34841700-0 2021 Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells. Decitabine 0-10 tumor protein p53 Homo sapiens 60-63 34226168-8 2021 Treatment response to CR or PR and TP53 mutation were 2 prognostic factor for OS and PFS in decitabine with CEG regimen. Decitabine 92-102 tumor protein p53 Homo sapiens 35-39 34534222-11 2021 These findings may emphasis that 5-AzaD is effective in treatment of HPV(-) HNSCC tumours through TP53 independent pathway. Decitabine 33-39 tumor protein p53 Homo sapiens 98-102 35236053-0 2022 Decitabine salvage for Tumor Protein P53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. Decitabine 0-10 tumor protein p53 Homo sapiens 37-40 35237000-0 2022 Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation. Decitabine 14-24 tumor protein p53 Homo sapiens 99-103